Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 16 articles:
HTML format



Single Articles


    July 2025
  1. HE D, Zhang L, Yu L, Zhang Y, et al
    Fine structural design of 3betaHSD1 inhibitors for prostate cancer therapy.
    Proc Natl Acad Sci U S A. 2025;122:e2422267122.
    PubMed     Abstract available


  2. SUSHENTSEV N, Hamm G, Manavaki R, McLean MA, et al
    Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2502423122.
    PubMed     Abstract available


    June 2025
  3. PAPPAS K, Ferrari M, Smith P, Nandakumar S, et al
    BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.
    Proc Natl Acad Sci U S A. 2025;122:e2426743122.
    PubMed     Abstract available


    April 2025

  4. Correction for Pitzen et al., Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2504762122.
    PubMed    


    March 2025
  5. LEE J, Park J, Hur Y, Um D, et al
    ETV5 reduces androgen receptor expression and induces neural stem-like properties during neuroendocrine prostate cancer development.
    Proc Natl Acad Sci U S A. 2025;122:e2420313122.
    PubMed     Abstract available


    February 2025
  6. PITZEN SP, Rudenick AN, Qiu Y, Zhang W, et al
    Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2415308122.
    PubMed     Abstract available


    December 2024
  7. VARUZHANYAN G, Chen CC, Freeland J, He T, et al
    PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
    Proc Natl Acad Sci U S A. 2024;121:e2416882121.
    PubMed     Abstract available


    November 2024
  8. KOHRT SE, Novak EJ, Tapadar S, Wu B, et al
    Small-molecule disruption of androgen receptor-dependent chromatin clusters.
    Proc Natl Acad Sci U S A. 2024;121:e2406239121.
    PubMed     Abstract available


    October 2024
  9. WANG Z, Yu H, Bao W, Qu M, et al
    Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
    Proc Natl Acad Sci U S A. 2024;121:e2402741121.
    PubMed     Abstract available


    September 2024
  10. SU XA, Stopsack KH, Schmidt DR, Ma D, et al
    RAD21 promotes oncogenesis and lethal progression of prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2405543121.
    PubMed     Abstract available


    August 2024
  11. YU G, Corn PG, Mak CSL, Liang X, et al
    Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
    Proc Natl Acad Sci U S A. 2024;121:e2402903121.
    PubMed     Abstract available


    July 2024
  12. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
    USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Proc Natl Acad Sci U S A. 2024;121:e2403331121.
    PubMed     Abstract available


  13. ZAIDI S, Park J, Chan JM, Roudier MP, et al
    Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322203121.
    PubMed     Abstract available


    April 2024
  14. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    PubMed     Abstract available


    December 2023
  15. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
    Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
    Proc Natl Acad Sci U S A. 2023;120:e2312261120.
    PubMed     Abstract available


    November 2023
  16. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
    MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2307094120.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.